Livdelzi (Seladelpar Lysine) Patent Expiration, LOE Window & CMS Spending

Livdelzi (Seladelpar Lysine) by Gilead Sciences: FDA Orange Book core substance LOE 2027-09-13 (last listed 2038-03-13), 0 AB generics, $15.6M 2024 CMS Part D & Medicaid spend, and $12,606 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGilead Sciences
FDA Application & PathwayN217899 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2027-09-13
Last Listed Patent or Exclusivity Date2038-03-13
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$15.6M
2024 Medicare Part D Spend$13.7M
2024 Medicaid Spend$1.9M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($12,606 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.